Evidence map›Paper›PMID 40080089›Full record

ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2025

Big databases and biobanks for studying the links between CKD, cognitive impairment, and dementia.

Carmine Zoccali, Francesca Mallamaci, Kerry Rosenberg, Robert Unwin, Pedro Imenez Silva, Maria Adelina Simeoni, Gaye Hafez, Giovambattista Capasso, Dorothea Nitsch, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators

Abstract readReview
In one paragraph

Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carmine ZoccaliRenal Research Institute, New York, NY, USA.ORCID 0000-0002-6616-1996
Francesca MallamaciIFC-CNR, Institute of Clinical Physiology of Reggio Calabria, Italy.
Kerry RosenbergDepartment of Renal Medicine, University College London, London, UK.
Robert UnwinAstraZeneca, Cambridge, UK.
Pedro Imenez SilvaDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.
Maria Adelina SimeoniDepartment of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Caserta, Italy.
Gaye HafezDepartment of Pharmacology, Faculty of Pharmacy, Altinbas University, Istanbul, Turkey.
Giovambattista CapassoInstitute of Molecular Biology and Genetics (Biogem), Ariano Irpino (AV), Italy.
Dorothea NitschDepartment of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators

Funding

COST CA19127
6 · The paper itself

Abstract

Research on cognitive function in individuals with chronic kidney disease (CKD) is critical due to the significant public health challenge posed by both CKD and cognitive impairment. CKD affects approximately 10-15% of the adult population, with higher prevalence in the elderly, who are already at increased risk for cognitive decline. Cognitive impairment is notably higher in CKD patients, particularly those with severe stages of the disease, and progresses more rapidly in those on dialysis. This review explores how data from large biobank studies such as the Alzheimer's Disease Neuroimaging Initiative, UK Biobank, and others could be used to enhance understanding the progression and interplay between CKD and cognitive decline. Each of these data sources has specific strengths and limitations. Strengths include large sample sizes and longitudinal data across different groups, and in different settings. Addressing limitations leads to challenges in dealing with heterogeneous data collection methods, and addressing missing data, which requires the use of sophisticated statistical techniques. Combining data from multiple databases can mitigate individual study limitations, particularly via the 'epidemiological triangulation' concept. Using such data appropriately holds immense potential to better understand the pathobiology underlying CKD and cognitive impairment. Addressing the inherent challenges with a clear strategy is crucial for advancing our understanding and improving the lives of those affected by both CKD and cognitive impairment.

Indexed as

Big DataBiological Specimen BanksCognitive DysfunctionDatabases, FactualDementiaRenal Insufficiency, ChronicHumansbiobankchronic kidney diseasecognitive impairmentdementiaepidemiology

Identifiers

PMID40080089
PMCPMC11905747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.